Maria Giovanna Sabbieti

Parathyroid Hormone Regulates the Expression of Fibroblast Growth Factor-2 mRNA and Fibroblast Growth Factor Receptor mRNA in Osteoblastic Cells

We examined the effect of parathyroid hormone (PTH) on basic fibroblast growth factor‐2 (FGF‐2) and FGF receptor (FGFR) expression in osteoblastic MC3T3‐E1 cells and in neonatal mouse calvariae. Treatment of MC3T3‐E1 cells with PTH(1–34) (10–8M) or forskolin (FSK; 10–5M) transiently increased a 7 kb FGF‐2 transcript with a peak at 2 h. The PTH increase in FGF‐2 mRNA was maintained in the presence of cycloheximide. PTH also increased FGFR‐1 mRNA at 2 h and transiently increased FGFR‐2 mRNA at 1 h. FGFR‐3 and FGFR‐4 mRNA transcripts were not detected in MC3T3‐E1 cells. In cells transiently transfected with an 1800‐bp FGF‐2 promoter‐luciferase reporter, PTH and FSK increased luciferase activity at 2 h and 4 h. Immunohistochemistry showed that PTH and FSK increased FGF‐2 protein labeling in the nuclei of MC3T3‐E1 cells. PTH also increased FGF‐2 mRNA, and FGFR‐1 and FGFR‐2 mRNA levels within 30 minutes in neonatal mouse calvarial organ cultures. We conclude that PTH and cAMP stimulate FGF‐2 mRNA abundance in part through a transcriptional mechanism. PTH also regulated FGFR gene expression. We hypothesize that some effects of PTH on bone remodeling may be mediated by regulation of FGF‐2 and FGFR expression in osteoblastic cells.

Reduced expression and function of bone morphogenetic protein-2 in bones of Fgf2 null mice.

Disruption of the fibroblast growth factor 2 (FGF‐2) gene results in reduced bone mass in mice and impairs expression of bone morphogenic protein‐2 (BMP‐2) an important mediator of osteoblast and osteoclast differentiation. Since the relationship between FGF‐2 and BMP‐2 in bone remodeling has not been fully determined, in this study we examined whether endogenous FGF‐2 was necessary for maximal effect of BMP‐2 on periosteal bone formation in vivo and bone nodule formation and osteoclast formation in vitro in Fgf2−/− mice. We showed that BMP‐2 significantly increased periosteal bone formation by 57% in Fgf2+/+ mice but the changes were not significant in Fgf2−/− littermates. In line with these results we found no significant increase in alkaline phosphatase positive (ALP) activity in calvarial osteoblasts or ALP mineralized colonies in stromal cultures from Fgf2−/− mice after BMP‐2 treatment. Moreover, BMP‐2 induced osteoclast formation was also impaired in marrow stromal cultures from Fgf2−/− mice. Interestingly, BMP‐2 induced nuclear accumulation of the runt related transcription factor (Runx2) was markedly impaired in osteoblasts from Fgf2−/− mice. Examination of the effect of loss of FGF‐2 on BMP‐2 signaling pathway showed that BMP‐2 caused a similar induction of phospho‐Smad1/5/8 within 30 min in calvarial osteoblasts from both genotypes. In contrast BMP‐2‐induced p42/44 MAPK was reduced in Fgf2−/− mice. These findings strongly demonstrated that endogenous FGF‐2 is important in the maximal responses of BMP‐2 in bone and that this may be dependent on the p42/44 MAPK signaling pathway and downstream modulation of Runx2. J. Cell. Biochem. 103: 1975–1988, 2008.

Endogenous FGF-2 is critically important in PTH anabolic effects on bone.

Parathyroid hormone (PTH) increases fibroblast growth factor receptor‐1 (FGFR1) and fibroblast growth factor‐2 (FGF‐2) expression in osteoblasts and the anabolic response to PTH is reduced in Fgf2−/− mice. This study examined whether candidate factors implicated in the anabolic response to PTH were modulated in Fgf2−/− osteoblasts. PTH increased Runx‐2 protein expression in Fgf2+/+ but not Fgf2−/− osteoblasts. By immunocytochemistry, PTH treatment induced nuclear accumulation of Runx‐2 only in Fgf2+/+ osteoblasts. PTH and FGF‐2 regulate Runx‐2 via activation of the cAMP response element binding proteins (CREBs). Western blot time course studies showed that PTH increased phospho‐CREB within 15 min that was sustained for 24 h in Fgf2+/+ but had no effect in Fgf2−/− osteoblasts. Silencing of FGF‐2 in Fgf2+/+ osteoblasts blocked the stimulatory effect of PTH on Runx‐2 and CREBs phosphorylation. Studies of the effects of PTH on proteins involved in osteoblast precursor proliferation and apoptosis showed that PTH increased cyclinD1‐cdk4/6 protein in Fgf2+/+ but not Fgf2−/− osteoblasts. Interestingly, PTH increased the cell cycle inhibitor p21/waf1 in Fgf2−/− osteoblasts. PTH increased Bcl‐2/Bax protein ratio in Fgf2+/+ but not Fgf2−/− osteoblasts. In addition PTH increased cell viability in Fgf2+/+ but not Fgf2−/− osteoblasts. These data suggest that endogenous FGF‐2 is important in PTH effects on osteoblast proliferation, differentiation, and apoptosis. Reduced expression of these factors may contribute to the reduced anabolic response to PTH in the Fgf2−/− mice. Our results strongly indicate that the anabolic PTH effect is dependent in part on FGF‐2 expression. J. Cell. Physiol. 219: 143–151, 2009.

Polypyrrole-polysaccharide thin films characteristics: electrosynthesis and biological properties.

Polypyrrole-polysaccharide thin films were electropolymerized from starting solutions containing pyrrole and a polysaccharide, namely, heparin, chondroitin-4-sulphate or hyaluronic acid. The synthesized samples showed good chemical and physicochemical properties determined by the synthesis parameters such as the current density and time. For instance, the sample morphology was strictly correlated to the current density as follows: a smooth surface morphology was observed when the current density was in the range of 100-700 microA/cm(2), whereas high current (I > 1.0 mA/cm(2)) or longer time (synthesis charge > 100 mC/cm(2)) led to rough surfaces. The presence of polysaccharide within the polymeric matrix assured proper hydrophilicity to the samples. The optimized surface chemistry due to the presence of a polysaccharide and the controllable morphology allowed positive cell/substrate interactions and these are proved by cellular tests using MC3T3-E1 osteoblast cultures.

Involvement of p53 in Phthalate Effects on Mouse and Rat Osteoblasts

The role of two estrogen‐mimicking compounds in regulating osteoblast activities were examined. Previously, our attention was focused on benzyl butyl phthalate (BBP) and di‐n‐butyl phthalate (DBP) since previous works showed that they enter the cytoplasm, bioaccumulate, modify actin cytoarchitecture and exert mitogenic effects involving microfilament disruption, and nuclear actin and lamin A regulation in Py1a rat osteoblasts. In this study we showed that BBP and DBP cause DNA base lesions both in MT3T3‐E1 osteoblasts and in mouse primary calvarial osteoblasts (COBs). In addition, treatment with the above effectors caused an increase of p53 and phospho‐p53 (ser‐15 and ser‐20) as well as an increase of apoptotic proteins with consequent decrease of cell viability. Moreover, treatment with phthalates did not modified p53 and phospho‐p53 expression in Py1a rat osteoblasts. It is of relevance that in p53 knockdown mouse osteoblasts a proliferative effect of phthalates, similar to that observed in rat Py1a osteoblasts, was found. In conclusion, our data demonstrated that phthalates induce osteoblast apoptosis, which is, at least in part, mediated by p53 activation, suggesting that the proliferative effects could be due to p53 missing activation or p53 mutation. J. Cell. Biochem. 107: 316–327, 2009.

Prostaglandins differently regulate FGF-2 and FGF receptor expression and induce nuclear translocation in osteoblasts via MAPK kinase

We have previously reported that prostaglandin F2α (PGF2α) and its selective agonist fluprostenol increase basic fibroblast growth factor (FGF-2) mRNA and protein production in osteoblastic Py1a cells. The present report extends our previous studies by showing that Py1a cells express FGF receptor-2 (FGFR2) and that treatment with PGF2α or fluprostenol decreases FGFR2 mRNA. We have used confocal and electron microscopy to show that, under PGF2α stimulation, FGF-2 and FGFR2 proteins accumulate near the nuclear envelope and colocalize in the nucleus of Py1a cells. Pre-treatment with cycloheximide blocks nuclear labelling for FGF-2 in response to PGF2α. Treatment with SU5402 does not block prostaglandin-mediated nuclear internalization of FGF-2 or FGFR2. Various effectors have been used to investigate the signal transduction pathway. In particular, pre-treatment with phorbol 12-myristate 13-acetate (PMA) prevents the nuclear accumulation of FGF-2 and FGFR2 in response to PGF2α. Similar results are obtained by pre-treatment with the protein kinase C (PKC) inhibitor H-7. In addition, cells treated with PGF2α exhibit increased nuclear labelling for the mitogen-activated protein kinase (MAPK), p44/ERK2. Pre-treatment with PMA blocks prostaglandin-induced ERK2 nuclear labelling, as confirmed by Western blot analysis. We conclude that PGF2α stimulates nuclear translocation of FGF-2 and FGFR2 by a PKC-dependent pathway; we also suggest an involvement of MAPK/ERK2 in this process.

FGF-2 enhances Runx-2/Smads nuclear localization in BMP-2 canonical signaling in osteoblasts.

Bone morphogenetic protein 2 (BMP‐2) is one of the most potent regulators of osteoblast differentiation and bone formation. R‐Smads (Smads 1/5/8) are the major transducers for BMPs receptors and, once activated, they are translocated in the nucleus regulating transcription target genes by interacting with various transcription factors. Runx‐2 proteins have been shown to interact through their C‐terminal segment with Smads and this interaction is required for in vivo osteogenesis. In particular, recruitment of Smads to intranuclear sites is Runx‐2 dependent, and Runx‐2 factor may accommodate the dynamic targeting of signal transducer to active transcription sites. Previously, we have shown, by in vitro and in vivo experiments, that BMP‐2 up‐regulated FGF‐2 which is important for the maximal responses of BMP‐2 in bone. In this study, we found that endogenous FGF2 is necessary for BMP‐2 induced nuclear accumulation and co‐localization of Runx‐2 and phospho‐Smads1/5/8, while Runx/Smads nuclear accumulation and co‐localization was reduced in Fgf2−/− osteoblasts. Based on these novel data, we conclude that the impaired nuclear accumulation of Runx‐2 in Fgf2−/− osteoblasts reduces R‐Smads sub‐nuclear targeting with a consequent decreased expression of differentiating markers and impaired bone formation in Fgf2 null mice. J. Cell. Physiol. 228: 2149–2158, 2013.

Anti-apoptotic Bcl-2 enhancing requires FGF-2/FGF receptor 1 binding in mouse osteoblasts.

In this study, we investigated the role of prostaglandin F2α (PGF2α) in mouse osteoblast survival and the function of fibroblast growth factor 2 (FGF‐2) and fibroblast growth factor receptor 1 (FGFR1) in this process. In particular, for the first time, we demonstrated that PGF2α increased osteoblast survival in a dose‐dependent manner and we showed that the effect is correlated with an increase in Bcl‐2/Bax ratio. Furthermore, we demonstrated that PGF2α caused a decrement of the active caspases 9 and 3. By blocking FGF‐2 with the specific neutralizing antibody and by depletion of FGFR1 gene with a specific siRNA, we showed that FGFR1 and FGF‐2 are critical for the increment of Bcl‐2/Bax ratio and the decrement of the active caspases 9 and 3, induced by PGF2α. Moreover, transmission electron microscopy studies showed that PGF2α increased binding of FGF‐2 and FGFR1 and co‐localization of reactive sites at plasma membrane level. In conclusion, we report a novel mechanism in which PGF2α induces FGF‐2 binding to its specific cell surface receptor 1 leading to a cascade pathway that culminates with increased mouse osteoblast survival. J. Cell. Physiol. 214:145–152, 2008.

Prostaglandin F2α: A bone remodeling mediator

Prostaglandin F2α (PGF2α) plays multiple roles on bone metabolism by regulating a wide range of signaling pathways. PGF2α, via activation of PKC, stimulates Na‐dependent inorganic phosphate (Pi) transport system in osteoblasts; up‐regulates interleukin (IL)‐6 synthesis; increases vascular endothelial growth factor (VEGF). In addition, PGF2α acts as a strong mitogenic and survival agent on osteoblasts, and these effects are, at least in part, mediated by the binding of fibroblast growth factor‐2 (FGF‐2) to the specific receptor FGFR1. The understanding of PGF2α intracellular network, albeit complex to clarify, provides molecular bases useful to identify the players of osteoblast proliferation, apoptosis, and the associated angiogenic processes. Indeed, the molecular mechanism that underline PGF2α‐regulated bone metabolism may be a promising platform for the development of novel targeted therapies in the treatment of bone disorders and disease. J. Cell. Physiol. 228: 25–29, 2013.

Multihormonal control of vitellogenin mRNA expression in the liver of frog, Rana esculenta

In Rana esculenta in an in vitro system, hepatic vitellogenin synthesis can be induced by growth hormone in both sexes. In this study: (1) the ability of this hormone to induce transcription of the VTG gene was determined, and (2) this ability was compared with that of estradiol-17 beta. The results indicate that growth hormone stimulates VTG mRNA transcription both in vivo and in vitro, in both sexes. The levels of mRNA are related to protein levels in the medium. In addition, seasonal variation occurs in the VTG gene transcription under growth hormone and estradiol-17 beta; indeed the more active inducer was growth hormone during the reproductive period and estradiol-17 beta during the preproductive phase.